Year Published
- 2008 (0)
- 2009 (1) Apply 2009 filter
- 2010 (0)
- (-) Remove 2011 filter 2011
- 2012 (0)
- 2013 (0)
- 2014 (0)
- 2015 (2) Apply 2015 filter
- 2016 (2) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
Types of Research
Geography
- East Africa Region and Selected Countries (11) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (3) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (1) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (5) Apply Sub-Saharan Africa filter
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
Current search
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
- (-) Remove 2011 filter 2011
- (-) Remove Global filter Global
- (-) Remove Agricultural Productivity, Yield, & Constraints filter Agricultural Productivity, Yield, & Constraints
- (-) Remove Monitoring & Evaluation filter Monitoring & Evaluation
- (-) Remove 2017 filter 2017
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
This brief presents selected material from the Fourth African Agricultural Markets Program (AAMP) policy symposium, Agricultural Risks Management in Africa: Taking Stock of What Has and Hasn’t Worked, organized by the Alliance for Commodity Trade in Eastern and Southern Africa and the Common Market for Eastern and Southern Africa that took place in Lilongwe, Malawi, September 6-10, 2010. We draw almost exclusively from Rashid and Jayne’s summary, “Risk Management in African Agriculture: A review of experiences.” This article summarizes across the background papers, with major findings grouped into three broad categories: cross cutting, government-led policies, and modern instruments.